Want to see AIMD full AI Analyst Report?
AIMD Stock Chart & Stats
$1.40
-$0.05(-3.57%)
At close: 4:00 PM EDT
$1.40
-$0.05(-3.57%)
Day’s Range― - ―
52-Week Range$1.26 - $4.50
Previous CloseN/A
Volume31.95K
Average Volume (3M)78.00K
Market Cap
$11.25M
Enterprise Value$20.21M
Total Cash (Recent Filing)$2.84M
Total Debt (Recent Filing)$13.81M
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.89
Shares Outstanding8,524,542
10 Day Avg. Volume93,591
30 Day Avg. Volume77,998
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.93
Price to Sales (P/S)56.41
P/FCF Ratio-1.51
Enterprise Value/Market Cap1.80
Enterprise Value/Revenue1.12K
Enterprise Value/Gross Profit-4.24
Enterprise Value/Ebitda-2.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform Tech And Diversified PipelineAinos operates a platform strategy spanning exosome-based therapeutics and AI-enabled diagnostic sensors, giving durable optionality across drug development and diagnostics. This diversification reduces single-program dependency and creates multiple commercialization pathways if core technologies validate.
High Gross Margins On Revenue CaptureReported gross margins near 79–83% where revenue exists signal that products or assays could be highly scalable and margin-accretive once fixed R&D and SG&A costs are covered. Such structural margin potential supports attractive unit economics over a multi-quarter commercialization ramp.
Access To Bank Credit For Near-term LiquidityThe unsecured CTBC facility demonstrates a willing lender relationship and provides immediate runway without collateral or equity dilution. While short-term, this negotiated bank credit is a structural sign of financing access that can bridge operations and program milestones if followed by longer-term funding solutions.
Bears Say
Minimal And Declining RevenueTTM revenue of ~$18k and an ~85% YoY decline indicate virtually no commercial traction today. For a company with substantial fixed R&D and platform costs, persistently tiny revenue undermines sustainability and increases reliance on successful clinical/tech milestones to ever generate durable top-line growth.
Persistent Cash Burn And Weak Cash GenerationConsistent negative operating and free cash flow near -$4.4M TTM means the business requires ongoing external funding to operate. Structurally, this raises execution risk, limits internal investment capacity, and makes strategic planning contingent on securing capital or non-dilutive partnerships over multiple quarters.
Rising Leverage Increases Financing RiskDebt nearly twice equity for a loss-making biotech elevates refinancing and default risk. Higher leverage increases interest burden and reduces flexibility to fund R&D or pivot commercially, pressuring management to secure additional financing under potentially unfavorable terms if revenues do not materialize.
Ainos News
AIMD FAQ
What was Ainos’s price range in the past 12 months?
Ainos lowest stock price was $1.26 and its highest was $4.50 in the past 12 months.
What is Ainos’s market cap?
Ainos’s market cap is $11.25M.
When is Ainos’s upcoming earnings report date?
Ainos’s upcoming earnings report date is Aug 18, 2026 which is in 18 days.
How were Ainos’s earnings last quarter?
Ainos released its earnings results on May 13, 2026. The company reported -$0.408 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.408.
Is Ainos overvalued?
According to Wall Street analysts Ainos’s price is currently Overvalued.
Does Ainos pay dividends?
Ainos does not currently pay dividends.
What is Ainos’s EPS estimate?
Ainos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ainos have?
Ainos has 8,524,542 shares outstanding.
What happened to Ainos’s price movement after its last earnings report?
Ainos reported an EPS of -$0.408 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.585%.
Which hedge fund is a major shareholder of Ainos?
Currently, no hedge funds are holding shares in AIMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ainos
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Soligenix
―
Chemomab Therapeutics
―
―
FibroBiologics, Inc.
―
Ownership Overview
41.69% Insiders
0.37% Mutual Funds
0.30% Other Institutional Investors
57.45% Public Companies and
Individual Investors